Data as of Oct 21
| +0.34 / +1.44%|
The 8 analysts offering 12-month price forecasts for Tetraphase Pharmaceuticals Inc have a median target of 28.00, with a high estimate of 33.00 and a low estimate of 22.00. The median estimate represents a +17.20% increase from the last price of 23.89.
The current consensus among 9 polled investment analysts is to Buy stock in Tetraphase Pharmaceuticals Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.